158 related articles for article (PubMed ID: 36581722)
1. An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection.
Tong Y; Li JX; Chang DH; Wang LZ; Cai WW; Bao Y; Cai R; Xiao YD
Ann Surg Oncol; 2023 Apr; 30(4):2007-2020. PubMed ID: 36581722
[TBL] [Abstract][Full Text] [Related]
2. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study.
Fan W; Zhu B; Yue S; Zheng X; Yuan G; Yu L; Huang W; Huang S; Wei W; Li F; Huang Z; Tang R; Fan H; Li Z; Qiao L; Huang F; Cheng Y; Zhang Y; Wu Y; Zou X; Xue M; Wang H; Li J
Eur Radiol; 2023 Apr; 33(4):2809-2820. PubMed ID: 36562786
[TBL] [Abstract][Full Text] [Related]
4. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
5. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
6. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
7. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.
Zhang XP; Wang K; Wei XB; Li LQ; Sun HC; Wen TF; Chai ZT; Chen ZH; Shi J; Guo WX; Xie D; Cong WM; Wu MC; Lau WY; Cheng SQ
Oncologist; 2019 Dec; 24(12):e1476-e1488. PubMed ID: 31138726
[TBL] [Abstract][Full Text] [Related]
8. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
Wang Q; Xia D; Bai W; Wang E; Sun J; Huang M; Mu W; Yin G; Li H; Zhao H; Li J; Zhang C; Zhu X; Wu J; Li J; Gong W; Li Z; Lin Z; Pan X; Shi H; Shao G; Liu J; Yang S; Zheng Y; Xu J; Song J; Wang W; Wang Z; Zhang Y; Ding R; Zhang H; Yu H; Zheng L; Gu W; You N; Wang G; Zhang S; Feng L; Liu L; Zhang P; Li X; Chen J; Xu T; Zhou W; Zeng H; Zhang Y; Huang W; Jiang W; Zhang W; Shao W; Li L; Niu J; Yuan J; Li X; Lv Y; Li K; Yin Z; Xia J; Fan D; Han G;
J Hepatol; 2019 May; 70(5):893-903. PubMed ID: 30660709
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.
Jiang JH; Guo Z; Lu HF; Wang XB; Yang HJ; Yang FQ; Bao SY; Zhong JH; Li LQ; Yang RR; Xiang BD
World J Gastroenterol; 2015 Apr; 21(15):4627-34. PubMed ID: 25914472
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
11. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
12. Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders.
Demirtas CO; Ricco G; Ozdogan OC; Baltacioglu F; Ones T; Yumuk PF; Dulundu E; Uzun S; Colombatto P; Oliveri F; Brunetto MR; Gunduz F
Hepatol Commun; 2022 Mar; 6(3):633-645. PubMed ID: 34751001
[TBL] [Abstract][Full Text] [Related]
13. Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection.
Sun HC; Xie L; Yang XR; Li W; Yu J; Zhu XD; Xia Y; Zhang T; Xu Y; Hu B; Du LP; Zeng LY; Ouyang J; Zhang W; Song TQ; Li Q; Shi YH; Zhou J; Qiu SJ; Liu Q; Li YX; Tang ZY; Shyr Y; Shen F; Fan J
Chin Med J (Engl); 2017 Nov; 130(22):2650-2660. PubMed ID: 29133751
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
15. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
16. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
17. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
Li J; Yang S; Li Y; Li C; Xia Y; Zhu S; Xia J
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1295-1303. PubMed ID: 35835873
[TBL] [Abstract][Full Text] [Related]
18. Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients.
Jia K; Yin W; Gao Z; Shen W; Wang F; Xie S; Li M; Lv R
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):461-470. PubMed ID: 36827534
[TBL] [Abstract][Full Text] [Related]
19. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Sharma R
Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
[TBL] [Abstract][Full Text] [Related]
20. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]